Novel

Anaplastic lymphoma receptor tyrosine kinase (ALK) fluorescence in situ hybridization (FISH) immunohistochemistry (IHC) lung adenocarcinoma mRNA in situ hybridization (mRNA-ISH)

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
Apr 2020
Historique:
entrez: 19 5 2020
pubmed: 19 5 2020
medline: 19 5 2020
Statut: ppublish

Résumé

A recent technical advance in mRNA The study included 279 surgically resected lung adenocarcinomas and 44 transbronchial-biopsied (TBB) adenocarcinomas. mRNA-ISH was conducted using the RNAscope 2.0 system, which includes pre-designed probes for detecting the tyrosine kinase domain encoded in ALK protein expression was detected in 11 of 279 specimens (3.9%). The

Sections du résumé

BACKGROUND BACKGROUND
A recent technical advance in mRNA
METHODS METHODS
The study included 279 surgically resected lung adenocarcinomas and 44 transbronchial-biopsied (TBB) adenocarcinomas. mRNA-ISH was conducted using the RNAscope 2.0 system, which includes pre-designed probes for detecting the tyrosine kinase domain encoded in
RESULTS RESULTS
ALK protein expression was detected in 11 of 279 specimens (3.9%).
CONCLUSIONS CONCLUSIONS
The

Identifiants

pubmed: 32420065
doi: 10.21037/tlcr.2020.03.04
pii: tlcr-09-02-257
pmc: PMC7225155
doi:

Types de publication

Journal Article

Langues

eng

Pagination

257-268

Informations de copyright

2020 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.03.04). The authors have no conflicts of interest to declare.

Références

Clin Cancer Res. 2010 Mar 1;16(5):1561-71
pubmed: 20179225
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
Clin Cancer Res. 2015 Aug 15;21(16):3631-9
pubmed: 25567908
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
Lancet Oncol. 2012 Oct;13(10):1011-9
pubmed: 22954507
Ann Surg Oncol. 2010 Mar;17(3):889-97
pubmed: 20183914
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
J Thorac Oncol. 2013 Jan;8(1):45-51
pubmed: 23196275
J Mol Diagn. 2013 Jul;15(4):415-53
pubmed: 23562183
Oncologist. 2015 Mar;20(3):316-22
pubmed: 25721120
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
J Thorac Oncol. 2018 Mar;13(3):323-358
pubmed: 29396253
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
J Thorac Oncol. 2013 Jul;8(7):e67-8
pubmed: 23774392
Clin Cancer Res. 2009 Aug 15;15(16):5216-23
pubmed: 19671850
Mol Cancer. 2010 Jul 13;9:188
pubmed: 20624322
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Eur J Cancer. 2010 Jul;46(10):1773-80
pubmed: 20418096
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469

Auteurs

Noriko Hirai (N)

Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Takaaki Sasaki (T)

Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Shunsuke Okumura (S)

Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Masatoshi Sado (M)

Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Naoko Akiyama (N)

Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Masahiro Kitada (M)

Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Breast Disease Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Hidehiro Takei (H)

Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Yoshinobu Ohsaki (Y)

Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Classifications MeSH